10. Therapeutic Efficacy of Antiepileptic Drugs

  1. James W. Wheless
  1. James W. Wheless

Published Online: 1 NOV 2012

DOI: 10.1002/9781119998600.ch10

Epilepsy in Children and Adolescents

Epilepsy in Children and Adolescents

How to Cite

Wheless, J. W. (2012) Therapeutic Efficacy of Antiepileptic Drugs, in Epilepsy in Children and Adolescents (ed J. W. Wheless), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9781119998600.ch10

Editor Information

  1. Department of Pediatric Neurology, University of Tennessee Health Science Center, Le Bonheur Comprehensive Epilepsy Program and Neuroscience Institute, Le Bonheur Children's Hospital, Memphis, TN, USA

Author Information

  1. Department of Pediatric Neurology, University of Tennessee Health Science Center, Le Bonheur Comprehensive Epilepsy Program and Neuroscience Institute, Le Bonheur Children's Hospital, Memphis, TN, USA

Publication History

  1. Published Online: 1 NOV 2012
  2. Published Print: 23 NOV 2012

ISBN Information

Print ISBN: 9780470741238

Online ISBN: 9781119998600

SEARCH

Keywords:

  • antiepileptic drug;
  • efficacy-based treatment;
  • guideline;
  • randomized controlled trial;
  • expert consensus;
  • broad spectrum;
  • narrow spectrum

Summary

This chapter primarily focuses on the efficacy of antiepileptic drugs, while realizing that many other factors are critical in drug selection (e.g., adverse effect profile, pharmacology, etc.). The challenge the clinician faces is selecting the antiepileptic drug that is efficacious for a given seizure type or epilepsy syndrome, and applying the results of large population-based studies to their individual patient. The importance of the correct diagnosis cannot be overstated. Current efficacy-based treatment guidelines and algorithms are described, as are drug therapies that have regulatory approval in children, antiepileptic drugs for which randomized controlled trials have been conducted in a given epilepsy syndrome, and recommendations for treatment using the expert consensus method. Drug selection for specific pediatric epilepsy syndromes, and how choices can be affected by comorbidities, are considered.